PMID- 36401426
OWN - NLM
STAT- MEDLINE
DCOM- 20221122
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 101
IP  - 46
DP  - 2022 Nov 18
TI  - Efficacy and safety of metronomic chemotherapy in maintenance therapy for 
      metastatic colorectal cancer: A systematic review of randomized controlled 
      trials.
PG  - e31659
LID - 10.1097/MD.0000000000031659 [doi]
LID - e31659
AB  - BACKGROUND: The current studies on metronomic chemotherapy in mCRC are all aimed 
      at patients after multi-line therapy failure, and only a few studies have focused 
      on maintenance treatment after successful first-line therapy. METHODS: The 
      PubMed, Embase, Cochrane Library, Wanfang, CNKI, and VIP were searched, and the 
      relevant data was extracted, including media progression-free survival (mPFS), 
      media overall survival (mOS), and grade 3/4 adverse events (AEs). RESULTS: We 
      included 4 randomized controlled trials (RCTs), 2 RCTs showed that metronomic 
      maintenance chemotherapy could significantly improve mPFS compared to observation 
      group; another RCT showed that metronomic maintenance chemotherapy group did not 
      have low mPFS than the bevacizumab maintenance treatment (MT). The final RCT 
      showed that dual-agent metronomic chemotherapy combined with bevacizumab MT did 
      not improve mPFS compared with bevacizumab MT. The 3 RCTs showed that the 
      metronomic maintenance therapy could not effectively improve mOS in mCRC compared 
      to observation group or bevacizumab MT, while another RCT reported that the mOS 
      in metronomic maintenance chemotherapy group was similar to bevacizumab MT. AEs 
      was mostly mild and manageable. Grade >/= 3 AEs are mostly nonhematological 
      toxicity, and no deaths related to AEs were reported. CONCLUSION: This systematic 
      review indicates that metronomic chemotherapy for mCRC MT can improve mPFS in 
      some patients and is relatively safe. However, improvements in OS in most RCTs 
      are arguable. Therefore, we need further studies to verify its long-term 
      efficacy.
CI  - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Chen, Li
AU  - Chen L
AD  - Department of Pharmacy, Wusheng People's Hospital, Wusheng county, Guangan, 
      Sichuan, China.
FAU - Cao, Xin
AU  - Cao X
AD  - General Practice Department, Clinical Medical College and The First Affiliated 
      Hospital of North Sichuan Medical College, Nanchong, SiChuan, China.
FAU - Li, Jing
AU  - Li J
AD  - Department of Pharmacy, Clinical Medical College and The First Affiliated 
      Hospital of Chengdu Medical College, Chengdu, SiChuan, China.
FAU - Liu, ChaoMin
AU  - Liu C
AD  - Department of Oncology, Clinical Medical College and The First Affiliated 
      Hospital of Chengdu Medical College, Chengdu, SiChuan, China.
FAU - Jiang, Ting
AU  - Jiang T
AUID- ORCID: 0000-0002-4392-5631
AD  - Department of Pharmacy, Clinical Medical College and The First Affiliated 
      Hospital of Chengdu Medical College, Chengdu, SiChuan, China.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Humans
MH  - Bevacizumab/adverse effects
MH  - *Colorectal Neoplasms/pathology
MH  - Randomized Controlled Trials as Topic
MH  - *Colonic Neoplasms/drug therapy
MH  - *Rectal Neoplasms/drug therapy
MH  - *Lymphoma, Follicular/drug therapy
PMC - PMC9678531
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2022/11/20 06:00
MHDA- 2022/11/23 06:00
PMCR- 2022/11/18
CRDT- 2022/11/19 01:04
PHST- 2022/11/19 01:04 [entrez]
PHST- 2022/11/20 06:00 [pubmed]
PHST- 2022/11/23 06:00 [medline]
PHST- 2022/11/18 00:00 [pmc-release]
AID - 00005792-202211180-00065 [pii]
AID - 10.1097/MD.0000000000031659 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2022 Nov 18;101(46):e31659. doi: 
      10.1097/MD.0000000000031659.